The CGTLive™ Oncology specialty topic page highlights the latest clinical care news related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various cancers. It also houses video interviews with key opinion leaders in the field of oncology speaking to the related FDA actions, clinical guideline updates, and clinical trial findings in the field of gene and cell therapy for oncologic diseases.
May 3rd 2024
Review top news and interview highlights from the week ending May 3, 2024.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma
May 3rd 2021Dr. Abramson discusses the significance of the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.
EU Approval Sought for Cilta-Cel in Relapsed/Refractory Multiple Myeloma
April 30th 2021A marketing authorization application has been submitted to the European Medicines Agency for the approval of the CAR T-cell therapy ciltacabtagene autoleucel in the treatment of patients with relapsed and/or refractory multiple myeloma.
FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma
April 21st 2021The FDA granted a Regenerative Medicine Advanced Therapy designation to the allogeneic chimeric antigen receptor T-cell therapy as a potential treatment for patients with relapsed/refractory multiple myeloma.
FDA Approves Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
March 27th 2021The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Dr. Shah on the Potential Rationale for Selecting Ide-Cel Vs Cilta-Cel In Multiple Myeloma
March 26th 2021Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.